NYSE:AMRX - Amneal Pharmaceuticals Stock Price, Forecast & News

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Amneal Pharmaceuticals Inc (NYSE:AMRX) posted its quarterly earnings data on Wednesday, November, 6th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.13 by $0.09. The business earned $378.30 million during the quarter, compared to analyst estimates of $403.90 million. Amneal Pharmaceuticals had a negative net margin of 19.61% and a positive return on equity of 23.17%. Amneal Pharmaceuticals's revenue for the quarter was down 20.6% on a year-over-year basis. During the same quarter last year, the business earned $0.28 earnings per share. View Amneal Pharmaceuticals' Earnings History.

Amneal Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Amneal Pharmaceuticals.

12 brokerages have issued 1 year target prices for Amneal Pharmaceuticals' shares. Their forecasts range from $2.50 to $14.00. On average, they anticipate Amneal Pharmaceuticals' stock price to reach $6.30 in the next year. This suggests a possible upside of 23.5% from the stock's current price. View Analyst Price Targets for Amneal Pharmaceuticals.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 2 sell ratings, 6 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amneal Pharmaceuticals.

Media coverage about AMRX stock has been trending extremely negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amneal Pharmaceuticals earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Amneal Pharmaceuticals.

Amneal Pharmaceuticals saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 4,960,000 shares, a decrease of 13.9% from the December 15th total of 5,760,000 shares. Based on an average trading volume of 2,900,000 shares, the days-to-cover ratio is presently 1.7 days. Currently, 6.0% of the shares of the company are short sold. View Amneal Pharmaceuticals' Current Options Chain.

Some companies that are related to Amneal Pharmaceuticals include Ascendis Pharma A/S (ASND), Arrowhead Pharmaceuticals (ARWR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Evotec (EVTCY), United Therapeutics (UTHR), Allakos (ALLK), Blueprint Medicines (BPMC), SAGE Therapeutics (SAGE), Nektar Therapeutics (NKTR), HUTCHISON CHINA/S (HCM), FibroGen (FGEN), Mirati Therapeutics (MRTX), GW Pharmaceuticals PLC- (GWPH) and Deciphera Pharmaceuticals (DCPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Exelixis (EXEL), Nektar Therapeutics (NKTR), Canopy Growth (CGC), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Progenics Pharmaceuticals (PGNX) and Sorrento Therapeutics (SRNE).

Amneal Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include FNY Investment Advisers LLC (0.02%) and Assenagon Asset Management S.A. (0.01%). Company insiders that own Amneal Pharmaceuticals stock include Andrew S Boyer, Bryan M Reasons, International Ltd Fosun, Joseph Todisco, Nikita Shah, Paul Bisaro, Peter R Terreri, Pradeep Bhadauria and Ted C Nark. View Institutional Ownership Trends for Amneal Pharmaceuticals.

AMRX stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A.. View Insider Buying and Selling for Amneal Pharmaceuticals.

AMRX stock was bought by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have bought Amneal Pharmaceuticals stock in the last two years include Andrew S Boyer, International Ltd Fosun, Joseph Todisco, Paul Bisaro, Pradeep Bhadauria and Ted C Nark. View Insider Buying and Selling for Amneal Pharmaceuticals.

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AMRX stock can currently be purchased for approximately $5.10.

Amneal Pharmaceuticals has a market capitalization of $1.53 billion and generates $1.86 billion in revenue each year. The company earns $-169,730,000.00 in net income (profit) each year or $0.95 on an earnings per share basis. Amneal Pharmaceuticals employs 6,000 workers across the globe.View Additional Information About Amneal Pharmaceuticals.

The official website for Amneal Pharmaceuticals is http://www.amneal.com/.

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]